Jonathan Miller
Stock Analyst at Evercore ISI Group
(n/a)
# 4,740
Out of 5,090 analysts
6
Total ratings
n/a
Success rate
-38.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Reinstates: Outperform | $13 | $6.43 | +102.18% | 1 | Nov 26, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $9.61 | -16.75% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $2.34 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $10.34 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $3.10 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $21.15 | - | 1 | Jan 6, 2021 |
Aura Biosciences
Nov 26, 2025
Reinstates: Outperform
Price Target: $13
Current: $6.43
Upside: +102.18%
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $9.61
Upside: -16.75%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.34
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.34
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.10
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.15
Upside: -